The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Treatment options for COVID-19: The reality and challenges
Open accessAbstract
An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed by 100 mg once daily) is on-going. The other excellent anti-influenza RdRp inhibitor favipiravir is also being clinically evaluated for its efficacy in COVID-19 patients. The protease inhibitor lopinavir/ritonavir (LPV/RTV) alone is not shown to provide better antiviral efficacy than standard care. However, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV in vitro. Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus azithromycin (500 mg on day 1, followed by 250 mg once daily on day 2-5), which showed excellent clinical efficacy on Chinese COVID-19 patients and anti-SARS-CoV-2 potency in vitro. The roles of teicoplanin (which inhibits the viral genome exposure in cytoplasm) and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are under investigation. Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II type I receptor blockers is advised for COVID-19 patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263 · cited 1×
“It is noteworthy that adults with coronavirus disease 2019 (COVID-19) often present with a profound decrease in both CD4þ and CD8þ T-cell subsets at the early stage of this disease.(1,8) Subsequently, patients suffered acute respiratory distress syndrome for about 7e10 days after the onset of COVID19 due to rapid vira…”
BackgroundChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14817 · Cited by 3,559
To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C.-Y., Cai, J.-P., Chan, J. M.-C., Chik, T. S.-H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,066
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,911
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.03.005 · Cited by 1,160
Glowacka, I., Bertram, S., Müller, M. A., Allen, P., Soilleux, E., Pfefferle, S., Steffen, I., Tsegaye, T. S., He, Y., Gnirss, K., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02232-10 · Cited by 1,108
Liu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C., Zhang, M., Tan, J., Xu, Y., Song, R., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02374-0 · Cited by 1,082
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
de Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., & Feldmann, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922083117 · Cited by 887
Hofmann, H., Pyrc, K., van der Hoek, L., Geier, M., Berkhout, B., & Pöhlmann, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409465102 · Cited by 824
Are children less susceptible to COVID-19?
Lee, P.-I., Hu, Y.-L., Chen, P.-Y., Huang, Y.-C., & Hsueh, P.-R. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.02.011 · Cited by 655
Self-citation2019 Novel coronavirus: where we are and what we know
Cheng, Z. J., & Shan, J. (2020) · Infection · doi:10.1007/s15010-020-01401-y · Cited by 629
Luo, H., Tang, Q.-L., Shang, Y.-X., Liang, S.-B., Yang, M., Robinson, N., & Liu, J.-P. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3192-6 · Cited by 613
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
Protease inhibitors targeting coronavirus and filovirus entry
Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Nunneley, J. W., Barnard, D., Pöhlmann, S., McKerrow, J. H., Renslo, A. R., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.011 · Cited by 583
Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F., & Matsuyama, S. (2012) · Journal of Virology · doi:10.1128/jvi.00094-12 · Cited by 515
Brown, A. J., Won, J. J., Graham, R. L., Dinnon, K. H., Sims, A. C., Feng, J. Y., Cihlar, T., Denison, M. R., Baric, R. S., & Sheahan, T. P. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104541 · Cited by 510
Burke, R. M., Midgley, C. M., Dratch, A., Fenstersheib, M., Haupt, T., Holshue, M., Ghinai, I., Jarashow, M. C., Lo, J., McPherson, T. D., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6909e1 · Cited by 475
Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3362 · Cited by 445
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
Martinez, M. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00399-20 · Cited by 444
SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics
Cao, Q., Chen, Y.-C., Chen, C.-L., & Chiu, C.-H. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.02.009 · Cited by 411
Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists
Day, M. (2020) · BMJ · doi:10.1136/bmj.m1086 · Cited by 397
Yan, Y., Zou, Z., Sun, Y., Li, X., Xu, K.-F., Wei, Y., Jin, N., & Jiang, C. (2013) · Cell Research · doi:10.1038/cr.2012.165 · Cited by 353
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV
Lee, P.-I., & Hsueh, P.-R. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.02.001 · Cited by 327
Self-citationCovid-19 — The Search for Effective Therapy
Baden, L. R., & Rubin, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejme2005477 · Cited by 320
Arguments in favour of remdesivir for treating SARS-CoV-2 infections
Ko, W.-C., Rolain, J.-M., Lee, N.-Y., Chen, P.-L., Huang, C.-T., Lee, P.-I., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105933 · Cited by 316
Self-citationBacharier, L. B., Guilbert, T. W., Mauger, D. T., Boehmer, S., Beigelman, A., Fitzpatrick, A. M., Jackson, D. J., Baxi, S. N., Benson, M., Burnham, C.-A. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.13896 · Cited by 287
Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., Huang, F., Peng, T., Zhang, J., Liu, C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.716100 · Cited by 286
Treatment of COVID-19: old tricks for new challenges
Cunningham, A. C., Goh, H. P., & Koh, D. (2020) · Critical Care · doi:10.1186/s13054-020-2818-6 · Cited by 286
Evaluation of Ebola Virus Inhibitors for Drug Repurposing
Madrid, P. B., Panchal, R. G., Warren, T. K., Shurtleff, A. C., Endsley, A. N., Green, C. E., Kolokoltsov, A., Davey, R., Manger, I. D., Gilfillan, L., et al. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00030 · Cited by 247
Teicoplanin: an alternative drug for the treatment of COVID-19?
Baron, S. A., Devaux, C., Colson, P., Raoult, D., & Rolain, J.-M. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105944 · Cited by 243
A mouse model for MERS coronavirus-induced acute respiratory distress syndrome
Cockrell, A. S., Yount, B. L., Scobey, T., Jensen, K., Douglas, M., Beall, A., Tang, X.-C., Marasco, W. A., Heise, M. T., & Baric, R. S. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.226 · Cited by 206
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
Fedson, D. S., Opal, S. M., & Rordam, O. M. (2020) · mBio · doi:10.1128/mbio.00398-20 · Cited by 173
Beigel, J. H., Nam, H. H., Adams, P. L., Krafft, A., Ince, W. L., El-Kamary, S. S., & Sims, A. C. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.04.006 · Cited by 169
Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia
Jean, S., Chang, Y.-C., Lin, W.-C., Lee, W., Hsueh, P., & Hsu, C.-W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010275 · Cited by 167
Self-citationWang, Y., Fan, G., Salam, A., Horby, P., Hayden, F. G., Chen, C., Pan, J., Zheng, J., Lu, B., Guo, L., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz656 · Cited by 158
Fedson, D. S. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.11.03 · Cited by 124
Recommendations and guidelines for the treatment of pneumonia in Taiwan
Chou, C.-C., Shen, C., Chen, S., Chen, H.-M., Wang, Y.-C., Chang, W., Chang, Y.-T., Chen, W.-Y., Huang, C.-Y., Kuo, C.-C., et al. (2018) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2018.11.004 · Cited by 124
Beigel, J. H., Voell, J., Kumar, P., Raviprakash, K. S., Wu, H., Jiao, J., Sullivan, E. J., Luke, T. C., & Davey, R. T. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30002-1 · Cited by 115
2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China
Huang, W.-H., Teng, L.-C., Yeh, T.-K., Chen, Y.-J., Lo, W.-J., Wu, M.-J., Chin, C.-S., Tsan, Y., Lin, T., Chai, J., et al. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.02.009 · Cited by 87
Teicoplanin inhibits Ebola pseudovirus infection in cell culture
Wang, Y., Cui, R., Li, G., Gao, Q., Yuan, S., Altmeyer, R. M., & Zou, G. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.11.003 · Cited by 77
Asperen, R. M. W., Bos, A. P., Reinout, A., Dierdorp, B., Dekker, T., van Goor, H., Kamilić, J., van der Loos, C. M., van den Berg, E., Bruijn, M., et al. (2013) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3182a55735 · Cited by 58
Lee, K. H., Yoo, S. G., Cho, Y., Kwon, D. E., La, Y., Han, S. H., Kim, M. S., Choi, J. S., Kim, S. I., Kim, Y. S., et al. (2019) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2019.05.007 · Cited by 26
Cited by
Yoshimoto, F. K. (2020) · The Protein Journal · doi:10.1007/s10930-020-09901-4 · Cited by 543
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., & Yu, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00653-w · Cited by 339
Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US
Alcendor, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082442 · Cited by 332
Extra-respiratory manifestations of COVID-19
Lai, C.-C., Ko, W.-C., Lee, P.-I., Jean, S.-S., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106024 · Cited by 330
Self-citationDi Pierro, F., Iqtadar, S., Khan, A., Ullah Mumtaz, S., Masud Chaudhry, M., Bertuccioli, A., Derosa, G., Maffioli, P., Togni, S., Riva, A., et al. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s318949 · Cited by 180
Metadata
- Authors
- Jean, S.-S., Lee, P.-I., & Hsueh, P.-R.
- Venue
- Journal of Microbiology, Immunology and Infection
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 53
- Issue
- 3
- Pages
- 436-443
- ISSN
- 1684-1182 (ISSN-L)
- OpenAlex
- W3014356995
- Cited by
- 518
- References
- 65
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.